The investigation of FGF23, a prognostic factor in children with chronic kidney disease and bone metabolism
Not Applicable
Recruiting
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000028891
- Lead Sponsor
- Osaka Women's and Children's Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
The patients who does not agree with this study. The patients with anemia whose Hb levels are less than 8 g/dl
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does FGF23 signaling influence CKD progression and bone metabolism in pediatric patients?
What is the comparative effectiveness of FGF23 as a prognostic biomarker versus PTH and vitamin D in children with CKD?
Which biomarkers correlate with FGF23 levels to predict treatment response in pediatric CKD-related bone disease?
How does monitoring FGF23 levels aid in managing adverse bone metabolism events in children with CKD?
What are the interactions between FGF23, Klotho, and parathyroid hormone in CKD-induced bone disorders?